Logo image of ALTS

ALT5 SIGMA CORP (ALTS) Stock Fundamental Analysis

USA - NASDAQ:ALTS - US47089W1045 - Common Stock

2.04 USD
-0.12 (-5.56%)
Last: 10/21/2025, 8:00:00 PM
1.9818 USD
-0.06 (-2.85%)
After Hours: 10/21/2025, 8:00:00 PM
Fundamental Rating

2

ALTS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ALTS have multiple concerns. ALTS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ALTS has reported negative net income.
ALTS had a negative operating cash flow in the past year.
ALTS had negative earnings in 4 of the past 5 years.
In multiple years ALTS reported negative operating cash flow during the last 5 years.
ALTS Yearly Net Income VS EBIT VS OCF VS FCFALTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

1.2 Ratios

The Return On Assets of ALTS (-17.60%) is better than 61.78% of its industry peers.
Looking at the Return On Equity, with a value of -55.73%, ALTS is in line with its industry, outperforming 51.83% of the companies in the same industry.
Industry RankSector Rank
ROA -17.6%
ROE -55.73%
ROIC N/A
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTS Yearly ROA, ROE, ROICALTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 47.46%, ALTS is in the better half of the industry, outperforming 63.35% of the companies in the same industry.
In the last couple of years the Gross Margin of ALTS has grown nicely.
The Profit Margin and Operating Margin are not available for ALTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
ALTS Yearly Profit, Operating, Gross MarginsALTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

0

2. Health

2.1 Basic Checks

ALTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALTS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALTS has been increased compared to 5 years ago.
ALTS has a worse debt/assets ratio than last year.
ALTS Yearly Shares OutstandingALTS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALTS Yearly Total Debt VS Total AssetsALTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of 1.11, we must say that ALTS is in the distress zone and has some risk of bankruptcy.
ALTS's Altman-Z score of 1.11 is in line compared to the rest of the industry. ALTS outperforms 58.64% of its industry peers.
ALTS has a Debt/Equity ratio of 0.76. This is a neutral value indicating ALTS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.76, ALTS is doing worse than 69.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF N/A
Altman-Z 1.11
ROIC/WACCN/A
WACC8.68%
ALTS Yearly LT Debt VS Equity VS FCFALTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 0.88 indicates that ALTS may have some problems paying its short term obligations.
ALTS's Current ratio of 0.88 is on the low side compared to the rest of the industry. ALTS is outperformed by 85.86% of its industry peers.
ALTS has a Quick Ratio of 0.88. This is a bad value and indicates that ALTS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.88, ALTS is not doing good in the industry: 78.01% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.88
ALTS Yearly Current Assets VS Current LiabilitesALTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 74.35% over the past year.
Looking at the last year, ALTS shows a very strong growth in Revenue. The Revenue has grown by 926.05%.
Measured over the past years, ALTS shows a very negative growth in Revenue. The Revenue has been decreasing by -18.62% on average per year.
EPS 1Y (TTM)74.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-799%
Revenue 1Y (TTM)926.05%
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%194.05%

3.2 Future

Based on estimates for the next years, ALTS will show a very strong growth in Earnings Per Share. The EPS will grow by 28.61% on average per year.
Based on estimates for the next years, ALTS will show a very strong growth in Revenue. The Revenue will grow by 65.13% on average per year.
EPS Next Y-87.54%
EPS Next 2Y-4.52%
EPS Next 3Y28.61%
EPS Next 5YN/A
Revenue Next Year205.43%
Revenue Next 2Y125.77%
Revenue Next 3Y84.48%
Revenue Next 5Y65.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALTS Yearly Revenue VS EstimatesALTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
ALTS Yearly EPS VS EstimatesALTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTS Price Earnings VS Forward Price EarningsALTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALTS Per share dataALTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as ALTS's earnings are expected to grow with 28.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.52%
EPS Next 3Y28.61%

More info and screens

0

5. Dividend

5.1 Amount

ALTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALT5 SIGMA CORP

NASDAQ:ALTS (10/21/2025, 8:00:00 PM)

After market: 1.9818 -0.06 (-2.85%)

2.04

-0.12 (-5.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10
Inst Owners14.98%
Inst Owner Change0%
Ins Owners0.62%
Ins Owner Change0%
Market Cap223.62M
Analysts82.86
Price Target18.36 (800%)
Short Float %10.41%
Short Ratio1.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25%
PT rev (3m)-25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-100%
EPS NY rev (1m)0%
EPS NY rev (3m)-101.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.05
P/FCF N/A
P/OCF N/A
P/B 7.48
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.2
BVpS0.27
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.6%
ROE -55.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.46%
FCFM N/A
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.88
Altman-Z 1.11
F-Score4
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-799%
EPS Next Y-87.54%
EPS Next 2Y-4.52%
EPS Next 3Y28.61%
EPS Next 5YN/A
Revenue 1Y (TTM)926.05%
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%194.05%
Revenue Next Year205.43%
Revenue Next 2Y125.77%
Revenue Next 3Y84.48%
Revenue Next 5Y65.13%
EBIT growth 1Y2.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.09%
EBIT Next 3Y44.5%
EBIT Next 5Y44.66%
FCF growth 1Y-57.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.27%
OCF growth 3YN/A
OCF growth 5YN/A